Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Targeting the adenosine pathway for cancer immunotherapy.

Hammami A, Allard D, Allard B, Stagg J.

Semin Immunol. 2019 Apr;42:101304. doi: 10.1016/j.smim.2019.101304. Review.

PMID:
31604539
2.

The hepatic effects in dams that ingested 2-aminoanthracene during gestation and lactation.

Ulieme RE, Awer S, Stagg JC, Yau W, Gato WE.

Toxicol Ind Health. 2019 Sep 26:748233719875018. doi: 10.1177/0748233719875018. [Epub ahead of print]

PMID:
31558114
3.

Support for Breastfeeding Employees: Assessing Statewide Worksite Lactation Support Recognition Initiatives in the United States.

Reat A, Matthews KJ, Carver AE, Perez CA, Stagg J, Byrd-Williams CE.

J Hum Lact. 2019 Aug 22:890334419865902. doi: 10.1177/0890334419865902. [Epub ahead of print]

PMID:
31437403
4.

Adenosine A2a receptor promotes lymphangiogenesis and lymph node metastasis.

Allard B, Cousineau I, Allard D, Buisseret L, Pommey S, Chrobak P, Stagg J.

Oncoimmunology. 2019 Apr 26;8(8):1601481. doi: 10.1080/2162402X.2019.1601481. eCollection 2019.

PMID:
31413909
5.

Role of robot-assisted retroperitoneal lymph node dissection in malignant mesothelioma of the tunica vaginalis: case series and review of the literature.

Faraj KS, Abdul-Muhsin HM, Navaratnam AK, Rose KM, Stagg J, Ho TH, Bryce AH, Cheney SM, Tyson MD, Castle EP.

Can J Urol. 2019 Jun;26(3):9752-9757.

6.

WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors.

Gaudreau PO, Clairefond S, Class CA, Boulay PL, Chrobak P, Allard B, Azzi F, Pommey S, Do KA, Saad F, Trudel D, Young M, Stagg J.

Oncoimmunology. 2019 Mar 22;8(5):e1581545. doi: 10.1080/2162402X.2019.1581545. eCollection 2019.

PMID:
31069142
7.

A network approach to developing immuno-oncology combinations in Canada.

Higenell V, Fajzel R, Batist G, Cheema PK, McArthur HL, Melosky B, Morris D, Petrella TM, Sangha R, Savard MF, Sridhar SS, Stagg J, Stewart DJ, Verma S.

Curr Oncol. 2019 Apr;26(2):73-79. doi: 10.3747/co.26.4393. Epub 2019 Apr 1.

8.

Single-balloon enteroscopic retrograde cholangiopancreatography in the setting of altered upper gastrointestinal anatomy.

Smith S, Stagg J, Naumann C.

Proc (Bayl Univ Med Cent). 2018 Oct 26;31(4):467-469. doi: 10.1080/08998280.2018.1499315. eCollection 2018 Oct.

9.

Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers.

Gruosso T, Gigoux M, Manem VSK, Bertos N, Zuo D, Perlitch I, Saleh SMI, Zhao H, Souleimanova M, Johnson RM, Monette A, Ramos VM, Hallett MT, Stagg J, Lapointe R, Omeroglu A, Meterissian S, Buisseret L, Van den Eynden G, Salgado R, Guiot MC, Haibe-Kains B, Park M.

J Clin Invest. 2019 Apr 1;129(4):1785-1800. doi: 10.1172/JCI96313. Epub 2019 Mar 18.

10.

Moth pheromone-selective projection neurons with cell bodies in the antennal lobe lateral cluster exhibit diverse morphological and neurophysiological characteristics.

Lee SG, Celestino CF, Stagg J, Kleineidam C, Vickers NJ.

J Comp Neurol. 2019 May 15;527(9):1443-1460. doi: 10.1002/cne.24611. Epub 2019 Feb 5.

PMID:
30723902
11.

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.

Bahig H, Aubin F, Stagg J, Gologan O, Ballivy O, Bissada E, Nguyen-Tan FP, Soulières D, Guertin L, Filion E, Christopoulos A, Lambert L, Tehfe M, Ayad T, Charpentier D, Jamal R, Wong P.

BMC Cancer. 2019 Jan 14;19(1):68. doi: 10.1186/s12885-019-5266-4.

12.

Targeting the CD73-adenosine axis in immuno-oncology.

Allard D, Chrobak P, Allard B, Messaoudi N, Stagg J.

Immunol Lett. 2019 Jan;205:31-39. doi: 10.1016/j.imlet.2018.05.001. Epub 2018 May 24. Review.

PMID:
29758241
13.

Immuno-oncology-101: overview of major concepts and translational perspectives.

Allard B, Aspeslagh S, Garaud S, Dupont FA, Solinas C, Kok M, Routy B, Sotiriou C, Stagg J, Buisseret L.

Semin Cancer Biol. 2018 Oct;52(Pt 2):1-11. doi: 10.1016/j.semcancer.2018.02.005. Epub 2018 Feb 8. Review.

PMID:
29428479
14.

CD73-A2a adenosine receptor axis promotes innate B cell antibody responses to pneumococcal polysaccharide vaccination.

Allard D, Charlebois R, Gilbert L, Stagg J, Chrobak P.

PLoS One. 2018 Jan 29;13(1):e0191973. doi: 10.1371/journal.pone.0191973. eCollection 2018.

15.

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.

Buisseret L, Pommey S, Allard B, Garaud S, Bergeron M, Cousineau I, Ameye L, Bareche Y, Paesmans M, Crown JPA, Di Leo A, Loi S, Piccart-Gebhart M, Willard-Gallo K, Sotiriou C, Stagg J.

Ann Oncol. 2018 Apr 1;29(4):1056-1062. doi: 10.1093/annonc/mdx730.

16.

CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.

Turcotte M, Allard D, Mittal D, Bareche Y, Buisseret L, José V, Pommey S, Delisle V, Loi S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, Smyth MJ, Stagg J.

Cancer Res. 2017 Oct 15;77(20):5652-5663. doi: 10.1158/0008-5472.CAN-17-0707. Epub 2017 Aug 30.

17.

A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment.

Mediavilla-Varela M, Castro J, Chiappori A, Noyes D, Hernandez DC, Allard B, Stagg J, Antonia SJ.

Neoplasia. 2017 Jul;19(7):530-536. doi: 10.1016/j.neo.2017.02.004. Epub 2017 Jun 3.

18.

Erratum to: Maternal Mortality in Texas.

Baeva S, Archer NP, Ruggiero K, Hall M, Stagg J, Interis EC, Vega R, Delgado E, Hellerstedt J, Hankins G, Hollier LM; Texas Maternal Mortality and Morbidity Task Force.

Am J Perinatol. 2017 May;34(6):e2-e3. doi: 10.1055/s-0037-1600132. Epub 2017 Mar 22. No abstract available.

PMID:
28329894
19.

The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.

Allard B, Longhi MS, Robson SC, Stagg J.

Immunol Rev. 2017 Mar;276(1):121-144. doi: 10.1111/imr.12528. Review.

20.

Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.

Buisseret L, Garaud S, de Wind A, Van den Eynden G, Boisson A, Solinas C, Gu-Trantien C, Naveaux C, Lodewyckx JN, Duvillier H, Craciun L, Veys I, Larsimont D, Piccart-Gebhart M, Stagg J, Sotiriou C, Willard-Gallo K.

Oncoimmunology. 2016 Dec 14;6(1):e1257452. doi: 10.1080/2162402X.2016.1257452. eCollection 2017.

21.

Targeting A2 adenosine receptors in cancer.

Allard D, Turcotte M, Stagg J.

Immunol Cell Biol. 2017 Apr;95(4):333-339. doi: 10.1038/icb.2017.8. Epub 2017 Feb 8. Review.

PMID:
28174424
22.

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy.

Beavis PA, Henderson MA, Giuffrida L, Mills JK, Sek K, Cross RS, Davenport AJ, John LB, Mardiana S, Slaney CY, Johnstone RW, Trapani JA, Stagg J, Loi S, Kats L, Gyorki D, Kershaw MH, Darcy PK.

J Clin Invest. 2017 Mar 1;127(3):929-941. doi: 10.1172/JCI89455. Epub 2017 Feb 6.

23.

Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model.

Leung J, St-Onge P, Stagg J, Suh WK.

Cancer Immunol Immunother. 2017 Apr;66(4):491-502. doi: 10.1007/s00262-016-1950-2. Epub 2017 Jan 10.

PMID:
28074226
24.

Erratum to: Maternal Mortality in Texas.

Baeva S, Archer NP, Ruggiero K, Hall M, Stagg J, Interis EC, Vega R, Delgado E, Hellerstedt J, Hankins G, Hollier LM; Texas Maternal Mortality and Morbidity Task Force.

Am J Perinatol. 2017 May;34(6):e1. doi: 10.1055/s-0036-1597143. Epub 2016 Nov 28. No abstract available.

PMID:
27894130
25.

PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors.

Charlebois R, Allard B, Allard D, Buisseret L, Turcotte M, Pommey S, Chrobak P, Stagg J.

Cancer Res. 2017 Jan 15;77(2):312-319. doi: 10.1158/0008-5472.CAN-16-1873. Epub 2016 Nov 21.

26.

Maternal Mortality in Texas.

Baeva S, Archer NP, Ruggiero K, Hall M, Stagg J, Interis EC, Vega R, Delgado E, Hellerstedt J, Hankins G, Hollier LM; Texas Maternal Mortality and Morbidity Task Force.

Am J Perinatol. 2017 May;34(6):614-620. doi: 10.1055/s-0036-1595809. Epub 2016 Nov 9. Erratum in: Am J Perinatol. 2017 May;34(6):e1. Am J Perinatol. 2017 May;34(6):e2-e3.

PMID:
27829266
27.

Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies.

Allard B, Allard D, Stagg J.

Methods Mol Biol. 2016;1458:159-77. doi: 10.1007/978-1-4939-3801-8_12.

PMID:
27581021
28.

CD73-adenosine reduces immune responses and survival in ovarian cancer patients.

Gaudreau PO, Allard B, Turcotte M, Stagg J.

Oncoimmunology. 2016 Jan 19;5(5):e1127496. doi: 10.1080/2162402X.2015.1127496. eCollection 2016 May.

29.

Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis.

Mittal D, Sinha D, Barkauskas D, Young A, Kalimutho M, Stannard K, Caramia F, Haibe-Kains B, Stagg J, Khanna KK, Loi S, Smyth MJ.

Cancer Res. 2016 Aug 1;76(15):4372-82. doi: 10.1158/0008-5472.CAN-16-0544. Epub 2016 May 24.

30.

Immunosuppressive activities of adenosine in cancer.

Allard B, Beavis PA, Darcy PK, Stagg J.

Curr Opin Pharmacol. 2016 Aug;29:7-16. doi: 10.1016/j.coph.2016.04.001. Epub 2016 May 19. Review.

PMID:
27209048
31.

The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements.

Gaudreau PO, Stagg J, Soulières D, Saad F.

Biomark Cancer. 2016 May 5;8(Suppl 2):15-33. doi: 10.4137/BIC.S31802. eCollection 2016. Review.

32.

CD73-adenosine: a next-generation target in immuno-oncology.

Allard D, Allard B, Gaudreau PO, Chrobak P, Stagg J.

Immunotherapy. 2016 Feb;8(2):145-63. doi: 10.2217/imt.15.106. Epub 2016 Jan 25. Review.

PMID:
26808918
33.

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.

Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L, de Witte P, Dudek-Peric AM, Faggioni A, Fucikova J, Gaipl US, Golab J, Gougeon ML, Hamblin MR, Hemminki A, Herrmann M, Hodge JW, Kepp O, Kroemer G, Krysko DV, Land WG, Madeo F, Manfredi AA, Mattarollo SR, Maueroder C, Merendino N, Multhoff G, Pabst T, Ricci JE, Riganti C, Romano E, Rufo N, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Vacchelli E, Vandenabeele P, Vandenberk L, Van den Eynde BJ, Van Gool S, Velotti F, Zitvogel L, Agostinis P.

Front Immunol. 2015 Nov 20;6:588. doi: 10.3389/fimmu.2015.00588. eCollection 2015.

34.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HPV, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HMC, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M.

Semin Cancer Biol. 2015 Dec;35 Suppl:S276-S304. doi: 10.1016/j.semcancer.2015.09.007. Review.

35.

CD73: A potential biomarker for anti-PD-1 therapy.

Beavis PA, Slaney CY, Milenkovski N, Henderson MA, Loi S, Stagg J, Kershaw MH, Darcy PK.

Oncoimmunology. 2015 May 5;4(11):e1046675. eCollection 2015 Nov.

36.

CD73 is associated with poor prognosis in high-grade serous ovarian cancer.

Turcotte M, Spring K, Pommey S, Chouinard G, Cousineau I, George J, Chen GM, Gendoo DM, Haibe-Kains B, Karn T, Rahimi K, Le Page C, Provencher D, Mes-Masson AM, Stagg J.

Cancer Res. 2015 Nov 1;75(21):4494-503. doi: 10.1158/0008-5472.CAN-14-3569. Epub 2015 Sep 11.

37.

CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer.

Leclerc BG, Charlebois R, Chouinard G, Allard B, Pommey S, Saad F, Stagg J.

Clin Cancer Res. 2016 Jan 1;22(1):158-66. doi: 10.1158/1078-0432.CCR-15-1181. Epub 2015 Aug 7.

38.

A Mutation in the Carbohydrate Recognition Domain Drives a Phenotypic Switch in the Role of Galectin-7 in Prostate Cancer.

Labrie M, Vladoiu M, Leclerc BG, Grosset AA, Gaboury L, Stagg J, St-Pierre Y.

PLoS One. 2015 Jul 13;10(7):e0131307. doi: 10.1371/journal.pone.0131307. eCollection 2015.

39.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

40.

Co-blockade of immune checkpoints and adenosine A2A receptor suppresses metastasis.

Young A, Mittal D, Stannard K, Yong M, Teng MW, Allard B, Stagg J, Smyth MJ.

Oncoimmunology. 2014 Dec 15;3(10):e958952. eCollection 2014 Nov.

41.

Role of CD154 in cancer pathogenesis and immunotherapy.

Hassan GS, Stagg J, Mourad W.

Cancer Treat Rev. 2015 May;41(5):431-40. doi: 10.1016/j.ctrv.2015.03.007. Epub 2015 Mar 26. Review.

PMID:
25843228
42.

Immune evasion in cancer: Mechanistic basis and therapeutic strategies.

Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HMCS, Signori E, Honoki K, Georgakilas AG, Amin A, Helferich WG, Boosani CS, Guha G, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Fujii H, Aquilano K, Ashraf SS, Nowsheen S, Yang X, Choi BK, Kwon BS.

Semin Cancer Biol. 2015 Dec;35 Suppl:S185-S198. doi: 10.1016/j.semcancer.2015.03.004. Epub 2015 Mar 25. Review.

43.

The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis.

Spring K, Fournier P, Lapointe L, Chabot C, Roussy J, Pommey S, Stagg J, Royal I.

Oncogene. 2015 Oct 29;34(44):5536-47. doi: 10.1038/onc.2015.9. Epub 2015 Mar 16.

PMID:
25772245
44.

CD73 plays a protective role in collagen-induced arthritis.

Chrobak P, Charlebois R, Rejtar P, El Bikai R, Allard B, Stagg J.

J Immunol. 2015 Mar 15;194(6):2487-92. doi: 10.4049/jimmunol.1401416. Epub 2015 Feb 13.

45.

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.

Beavis PA, Milenkovski N, Henderson MA, John LB, Allard B, Loi S, Kershaw MH, Stagg J, Darcy PK.

Cancer Immunol Res. 2015 May;3(5):506-17. doi: 10.1158/2326-6066.CIR-14-0211. Epub 2015 Feb 11.

46.

Significance of 18F-Fluorodeoxyglucose Uptake at the Gastroesophageal Junction: Comparison of PET to Esophagogastroduodenoscopy.

Stagg J, Farukhi I, Lazaga F, Thompson C, Bradshaw L, Kaif M, Gould-Simon A, Schmidt R.

Dig Dis Sci. 2015 May;60(5):1335-42. doi: 10.1007/s10620-014-3456-0. Epub 2014 Dec 14.

PMID:
25502332
47.

Effects of salinity and prolactin on gene transcript levels of ion transporters, ion pumps and prolactin receptors in Mozambique tilapia intestine.

Seale AP, Stagg JJ, Yamaguchi Y, Breves JP, Soma S, Watanabe S, Kaneko T, Cnaani A, Harpaz S, Lerner DT, Grau EG.

Gen Comp Endocrinol. 2014 Sep 15;206:146-54. doi: 10.1016/j.ygcen.2014.07.020. Epub 2014 Aug 1.

PMID:
25088575
48.

Targeting cancer-derived adenosine: new therapeutic approaches.

Young A, Mittal D, Stagg J, Smyth MJ.

Cancer Discov. 2014 Aug;4(8):879-88. doi: 10.1158/2159-8290.CD-14-0341. Epub 2014 Jul 17. Review.

49.

Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.

Mittal D, Young A, Stannard K, Yong M, Teng MW, Allard B, Stagg J, Smyth MJ.

Cancer Res. 2014 Jul 15;74(14):3652-8. doi: 10.1158/0008-5472.CAN-14-0957. Epub 2014 Jul 1.

50.

Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.

Allard B, Turcotte M, Stagg J.

Expert Opin Ther Targets. 2014 Aug;18(8):863-81. doi: 10.1517/14728222.2014.915315. Epub 2014 May 6. Review.

PMID:
24798880

Supplemental Content

Support Center